Immunitor Inc.

Immunitor Inc. specializes in oral immunotherapies with a focus on developing tablet-based vaccines targeting hard-to-treat cancers such as hepatocellular carcinoma and infectious diseases like tuberculosis. The company has published numerous successful clinical trials over two decades, with its lead product V5 demonstrating unprecedented survival rates in late-stage liver cancer patients. Its oral vaccine technology platform has received key US patents covering both composition of matter and methods of use across a broad range of indications. Products have received Orphan Drug designations from the FDA, underscoring their potential impact on unmet medical needs.